Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Published:2003-10 Issue:9391 Volume:362 Page:1184-1191
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sorensen Per Soelberg,Ross Christian,Clemmesen Katja Maria,Bendtzen Klaus,Frederiksen Jette Lautrup,Jensen Kai,Kristensen Ole,Petersen Thor,Rasmussen Soren,Ravnborg Mads,Stenager Egon,Koch-Henriksen Nils

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial;Neurology,1993

2. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial;Neurology,1995

3. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial;Paty;Neurology,1993

4. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis;Jacobs;Ann Neurol,1996

5. Impact of interferon beta1a on neurologic disability in relapsing multiple sclerosis;Rudick;Neurology,1997

Cited by 328 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity;Clinical Immunology;2024-10

2. Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion;Meditsinskiy sovet = Medical Council;2024-08-14

3. Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN Trials;Hepatology;2024-04-17

4. An update on combination therapies for multiple sclerosis: where are we now?;Expert Review of Neurotherapeutics;2023-12-02

5. Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis;Clinical Immunology;2023-12